Regulus Therapeutics (RGLS) Stock Price Down 19.9%

Regulus Therapeutics Inc (NASDAQ:RGLS)’s share price fell 19.9% on Friday . The company traded as low as $1.17 and last traded at $1.17. 576,084 shares changed hands during mid-day trading, an increase of 69% from the average session volume of 340,945 shares. The stock had previously closed at $1.46.

A number of research firms have recently weighed in on RGLS. Zacks Investment Research lowered Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 11th. Wedbush set a $2.00 price objective on Regulus Therapeutics and gave the stock a “hold” rating in a research note on Friday, January 25th. One research analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. Regulus Therapeutics has an average rating of “Hold” and an average target price of $1.38.

The company has a market capitalization of $11.38 million, a price-to-earnings ratio of -0.10 and a beta of 2.26.

In other Regulus Therapeutics news, Director Stelios Papadopoulos acquired 50,000 shares of the company’s stock in a transaction dated Friday, December 28th. The stock was purchased at an average price of $1.09 per share, with a total value of $54,500.00. Following the completion of the purchase, the director now directly owns 835,073 shares in the company, valued at approximately $910,229.57. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.40% of the company’s stock.

A hedge fund recently raised its stake in Regulus Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) by 396.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 595,501 shares of the biopharmaceutical company’s stock after buying an additional 475,512 shares during the period. Renaissance Technologies LLC owned approximately 6.82% of Regulus Therapeutics worth $118,000 as of its most recent SEC filing. 46.22% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics (RGLS) Stock Price Down 19.9%” was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

See Also: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with's FREE daily email newsletter.